Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial

Taronger, Roser; Martínez-Cuenca, Susana; Ferreros, Inmaculada; Rubio, José María Rubio; Fernández-Colom, Pedro J.; Martínez-Triguero, María L.; Pellicer, António

doi:10.1016/j.ejogrb.2018.10.034

Cited by 5 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, we were not able to perform a metaanalysis comparing corifollitropin alfa with other stimulation protocols due to the lack of data. Very recently, Taronger et al (28) published the first RCT comparing the use of corifollitropin alfa versus highly purified menotropin in patients at risk of poor ovarian response. Despite similar reproductive outcomes, they could not demonstrate the noninferiority of corifollitropin alfa in regard to the OPR due to a wide confidence interval.…”

Section: Limitationsmentioning

confidence: 99%

Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials

Cozzolino

Vitagliano

Cecchino

et al. 2019

Fertility and Sterility

View full text Add to dashboard Cite

Objective: To evaluate the effectiveness of corifollitropin alfa in improving the success of IVF. Design: Systematic review and meta-analysis. Setting: Not applicable. Patient(s): Infertile women undergoing conventional IVF or intracytoplasmic sperm injection (ICSI). Intervention(s): Randomized controlled trials (RCTs) of infertile women undergoing a single IVF/ICSI cycle with either corifollitropin alfa or a conventional ovarian stimulation protocol based on daily injections. The review protocol was registered in PROSPERO before starting the data extraction (CRD42018088605). Main Outcome Measure(s): Primary outcomes were live birth rate and/or ongoing pregnancy rate. Clinical pregnancy rate, miscarriage rate, multiple pregnancies, number of oocytes and embryos obtained, cancellation rate, and rate of ovarian hyperstimulation syndrome and ectopic pregnancy were considered as secondary outcomes. Result(s): Eight randomized controlled trials were included; 2,345 women were assigned to the intervention group and 1,995 to the control group. The analysis of 4,340 IVF cycles did not reveal any difference in live birth rate and/or ongoing pregnancy rate between groups (risk ratio [RR], 0.92; 95% confidence interval [CI], 0.80-1.05). Similarly, no difference was found in clinical pregnancy rate (RR, 0.96; 95% CI, 0.88-1.05; I 2 ¼ 0%), miscarriage rate (RR, 0.94; 95% CI, 0.71-1.25; I 2 ¼ 0%), or multiple pregnancy rate (RR, 1.22; 95% CI, 0.99-1.50; I 2 ¼ 0%). Also, the rates of cycle cancellation, ovarian hyperstimulation syndrome, and ectopic pregnancy were similar in both groups. Sensitivity and subgroup analyses did not provide statistical changes to pooled results. Conclusion(s): Corifollitropin alfa seems to be an alternative for daily recombinant FSH injections in normal and poor responder patients undergoing ovarian stimulation in IVF/ICSI treatment cycles. (Fertil Steril Ò 2019;111:722-33. Ó2018 by American Society for Reproductive Medicine.) El resumen está disponible en Español al final del artículo.

show abstract

Section: Limitationsmentioning

confidence: 99%

Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials

Cozzolino

Vitagliano

Cecchino

et al. 2019

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

“…Low AMH patients do not have a good pregnancy prognosis, the number of oocytes retrieval is not high and the pregnancy rate is low [26][27][28][29][30]. Our study shows that even though age was <35 years, the patients with low AMH had significant low pregnancy compared to patients with high AMH.…”

Section: Discussionmentioning

confidence: 73%

Anti-Müllerian Hormone (AMH) is A Good Predictor for Ongoing Pregnancy in Women Undergoing IVF/ICSI in Antagonist Cycles

Sopa

2019

JGWH

View full text Add to dashboard Cite

We implemented the use of Anti-Müllerian hormone (AMH) as a biomarker for ovarian stimulation [14-16] since 2014. Our target was to achieve around 10 oocytes, with a range of 8-14. This was done by segmenting the patients into 3 groups given the maximum, standard or low dose of FSH stimulation according to their AMH levels. Materials and MethodsObservation cohort study, where data were retrospectively collected, by 888 patients undergoing their 2148 cycle antagonist

show abstract

“…It is important to say that results were shown to be unchanged after conforming patients to the Bologna criteria for poor ovarian response. 24 In the study by Taronger et al, 25 no differences were found for ongoing pregnancy rate, live birth rate, and the cumulative live birth rate per started cycle in potential poor responders using corifollitropin alfa plus hp-HMG or daily hp-HMG. Authors were not able to probe noninferiority of one to the other.…”

Section: Is Corifollitropin Alfa An Interesting Option For Poor Respo...mentioning

confidence: 90%

Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art

Carvalho

2023

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Physical and emotional burdens during the journey of infertile people through assisted reproductive technologies are sufficient to justify the efforts in developing patient-friendly treatment strategies. Thus, shorter duration of ovarian stimulation protocols and the need for less injections may improve adherence, prevent mistakes, and reduce financial costs. Therefore, the sustained follicle-stimulating action of corifollitropin alfa may be the most differentiating pharmacokinetic characteristic among available gonadotropins. In this paper, we gather the evidence on its use, aiming to provide the information needed for considering it as a first choice when a patient-friendly strategy is desired.

show abstract

Ovarian stimulation with corifollitropin alfa followed by hp-hMG compared to hp-hMG in patients at risk of poor ovarian response undergoing ICSI: A randomized controlled trial

Cited by 5 publications

References 26 publications

Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials

Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials

Anti-Müllerian Hormone (AMH) is A Good Predictor for Ongoing Pregnancy in Women Undergoing IVF/ICSI in Antagonist Cycles

Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art

Contact Info

Product

Resources

About